Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Modulight Q2'25 preview: Order book and increased number of care facilities support revenue

By Antti SiltanenAnalyst
Modulight

Translation: Original published in Finnish on 8/20/2025 at 7:52 am EEST.

Estimates Q2'24Q2'25Q2'25eQ2'25eConsensus2025e
MEUR / EUR ComparisonActualizedInderesConsensusHigh LowInderes
Revenue 0.97 1.73    8
EBIT -2.05 -1.72    -5.8
EPS (reported) -0.05 -0.04    -0.13
          
Revenue growth, % -12.80% 79.70%    94.60%
EBIT % (adj.) -212.10% -99.00%    -72.40%

Source: Inderes

Modulight will publish its Q2 results on Friday, August 22 at 1:00 pm EEST. Earlier this year, the company reported an increase in the order book and the number of hospitals using its products. Based on this message, we expect growing revenue for the quarter. However, our growth expectations are still moderate due to the early stage of the projects and low visibility. Our forecast indicates a slight upturn in earnings due to an increased gross margin. We expect operating expenses to remain flat year-on-year. The weakened dollar in the US impacts the company somewhat negatively, but at this stage, the company's ability to increase revenue and progress in achieving an earnings turnaround is key.

Order book and number of care facilities support revenue

In its Q4'24 report, Modulight reported its order book grew by 3 MEUR year-on-year. According to the report, the good progress also continued in early 2025. The number of care facilities using Modulight’s products grew from around ten per cent to around fifty in a year, which supports revenue in 2025. Our Q2 revenue forecast of 1.73 MEUR implies strong relative growth from the comparison period (Q1’24: 0.97 MEUR). However, the absolute estimate is still low relative to the company's cost structure and history. We expect the Phase III clinical trials announced in H2'23 to generate recurring revenue through ongoing patient enrollment. Revenue is also generated by the ophthalmic laser commercialized in the US starting from 2023, as well as several smaller projects, as is typical. The weakening of the dollar from April onward will likely create some headwinds for revenue, but the practical significance of exchange rates remains small.

Our EBIT forecast of -1.72 MEUR signals a mild improvement from the comparison period (Q2’24: -2.05 MEUR). The forecast is based on an improving gross margin and control of operating expenses. We expect depreciation to increase, which will weigh on the reported result. Reported figures for previous quarters and management's comments have indicated cost-cutting, as the number of personnel has fallen slightly. Other operating expenses have also been declining. We expect careful cost control to continue also this year. The company's cash assets are still substantial (net cash of 10.6 MEUR at the end of Q1’25), but profitable revenue growth naturally needs to start fairly soon to achieve an earnings turnaround and ensure sufficient cash reserves.

Expecting a year of budding growth and reduced losses

Modulight does not provide guidance, but the company's strategic goal for 2023-2025 is strong annual revenue growth and strong profitability at the EBITDA level. During the first two years of the strategy period, the targets were not met. We felt the Q4’24 and Q1’25 reports hinted at a better year in 2025. The signs are still cautious, and the progress of the earnings turnaround is therefore on an uncertain footing. For the full year 2025, we expect revenue of 8.0 MEUR, but we note that our forecasts have been overly optimistic so far. Our EBIT forecast for 2025 is -5.8 MEUR, which means an improvement on the comparison period (2024e: -8.1 MEUR). The view is based on growing revenue and gross margin, as well as continued tight cost control.

Login required

This content is only available for logged in users

Create account

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Read more on company page

Key Estimate Figures01.07.

202425e26e
Revenue4.18.010.8
growth-%1.7 %94.6 %36.1 %
EBIT (adj.)-8.3-5.8-4.6
EBIT-% (adj.)-203.5 %-72.4 %-42.4 %
EPS (adj.)-0.15-0.13-0.09
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Has there been any significant or noteworthy development in the IQM and Modulight quantum computing collaboration, or is it just a basic partnership...
yesterday
by Salkunvartija97
1
Good company presentation. Exuding confidence. Also remembered the 2024 talks about commercialization. Now said that there hasn’t been anything...
11/27/2025, 8:20 PM
by Jopinaattori
1
A new, just under half an hour long Modu and Orsila.https://youtu.be/tk0nQENR9DU?si=9MU7U32q6KifMSdf&t=4
11/27/2025, 7:14 PM
by Maakinen
3
My previous message in the thread 4 years ago. Modu designs lasers, which is potentially a very lucrative part of the value chain, if it can...
11/27/2025, 6:20 PM
by Clark kent
5
I also recently invested a bit in Modulight. I’ve also noticed the quietness; it’s clearly the quietest company among my investments.
11/27/2025, 3:19 PM
by Salkunvartija97
1
It’s quiet, regrettably quiet. Trading is almost at zero. This is how the years pass, big promises have turned into silence.
11/27/2025, 3:11 PM
by Skipper
1
Orsila has bought 21,000 units. A good sign for me.
10/29/2025, 9:08 AM
by Jopinaattori
8
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.